Saturday, July 28, 2007 9:02:11 AM
Any reason for GILD not to be happy about idix footing the bill for this trial? I imagine if we get similiar result for cost reasons Dr's will choose Hepsera.
Given that Viread and Baraclude work in similiar manners when patients relapse I'am guessing the hope here is that Dr's will put them on Hepsera. Is there any reason to think differently?
Any data yet available to compare Viread/Hepsera for patients relapsing?
Thank You for your time!
Randy
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
